Metastatic tumors in the pancreas: the role of endoscopic ultrasound-guided fine-needle aspiration

Betés, Maite; Vázquez, Santiago; Bojórquez, Alejandro; Lozano, Marı́a D.; Echeveste, José; Albarrán, Laura García; Navas, Miguel Muñoz; Súbtil, José Carlos

doi:10.17235/reed.2019.5914/2018

“…It has a poor survival rate, it mortality rate about 4.0% of all cancer deaths [78][79][80]. Now a day surgical resection is the only choice for treatment, however, only 20% of pancreatic cancer is surgically removable at the time of diagnosis [81][82][83]. The maximum survival rates are 22-26 months in patients who are undergoing surgical resection and taking adjuvant therapy resect able to improve survival [84][85][86][87] latest studies evaluating the effect of neoadjuvant therapy on highly picked patients with resect able disease have led to median survival life about 44 months in patients with R0 resection, node-negative disease [88][89][90].…”

Section: Palliative Care For Pancreatic Cancer Patientsmentioning

confidence: 99%

Palliative Care Therapies

Shanshal¹

2023

Supportive and Palliative Care and Quality of Life in Oncology

0

View full text Add to dashboard Cite

Palliative care considered as a support care for anyone living with a complex disease such as cancer, it has a great role in decreasing the severity of illness and slowness loss of functions by symptoms control and management in different stages of cancer. Palliative care is a specialized care area bounded to deliver health care facilities to patients who suffer from direct, indirect symptoms, unmet needs, for prevention and relief suffering from psychological issues mainly emotional issues (depression, anxiety, and delirium) and physiological issues like (nausea, vomiting, fatigue, xerostomia, headache, osteoradionecrosis, hemoptysis, dyspnea, taste loss, and pain). So its goal is to prolong their survival with the best possible quality of life for both the patients and their families.

show abstract

“…It has a poor survival rate, it mortality rate about 4.0% of all cancer deaths [78][79][80]. Now a day surgical resection is the only choice for treatment, however, only 20% of pancreatic cancer is surgically removable at the time of diagnosis [81][82][83]. The maximum survival rates are 22-26 months in patients who are undergoing surgical resection and taking adjuvant therapy resect able to improve survival [84][85][86][87] latest studies evaluating the effect of neoadjuvant therapy on highly picked patients with resect able disease have led to median survival life about 44 months in patients with R0 resection, node-negative disease [88][89][90].…”

Section: Palliative Care For Pancreatic Cancer Patientsmentioning

confidence: 99%

Supportive and Palliative Care and Quality of Life in Oncology

2023

1

0

View full text Add to dashboard Cite

The medical terms "supportive and palliative care" and "quality of life" in oncology refer to the two branches of medicine that address the emotional, social, ethical, spiritual, and treatment needs of cancer patients and their families, relatives, and healthcare providers. Additionally, the terms refer to the broader fields of palliative care and medicine that focus on helping individuals (sick and healthy) cope with the unpleasant side effects of cancer and its treatment and the proper way to enhance or maintain quality of life at an acceptable level.Maintaining or enhancing cancer patients' quality of life is just as crucial as whatever survival boost a pharmacological or non-pharmacological treatment may offer. Moreover, increased quality of life makes it more likely that patients and their families will stick with their treatments and that recovery will improve. This book focuses on palliative and supportive care and quality of life to assist physicians, pharmacists, nurses, and researchers in improving their knowledge, awareness, and practice in these areas. It provides up-to-date information and studies focused on these two aspects as they pertain to cancer patients.

show abstract

Solid Tumor Metastases to the Pancreas Diagnosed Using Fine-Needle Aspiration

Hou

¹

,

Stewart

²

,

Lee

³

et al. 2020

American Journal of Clinical Pathology

View full text Add to dashboard Cite

Abstract Objectives Solid tumor metastases to the pancreas are rare, and only limited literature on the topic is available. In this retrospective study, we reviewed 107 cases of solid tumor metastases to the pancreas diagnosed by fine-needle aspiration (FNA) from 2005 to 2019. Methods Information including the patients’ clinical histories, radiologic and pathologic findings, treatments, and follow-up were collected. Results The mean age of the patients was 62.4 years. The mean tumor size was 2.64 cm with even distribution throughout the pancreas (head, neck and body, and tail). The most common primary site was the kidney, followed by the lung, skin, and breast and the gynecologic, gastrointestinal, and genitourinary tracts. The most common tumor type was carcinoma, followed by melanoma and sarcoma. In comparison to patients with nonkidney primary cancers, those with primary renal cell carcinoma had a longer median interval between primary diagnosis and metastasis (8.5 vs 4.0 years; P < .01), less often had metastasis outside the pancreas (38% vs 74%; P < .01), and had a significantly longer 5-year survival rate (65.7% vs 24.8%; P < .01). Conclusions FNA plays a crucial role in diagnosing metastases to the pancreas. Metastases originating from kidney and nonkidney primary tumors have distinct clinicopathologic features and prognoses.

show abstract

Metastatic tumors in the pancreas: the role of endoscopic ultrasound-guided fine-needle aspiration

Cited by 5 publications

References 37 publications

Palliative Care Therapies

Palliative Care Therapies

Supportive and Palliative Care and Quality of Life in Oncology

Solid Tumor Metastases to the Pancreas Diagnosed Using Fine-Needle Aspiration

Contact Info

Product

Resources

About